Neal LeLeiko's research is currently focused on the natural history of inflammatory bowel disease in children. Most published information on the course of ulcerative colitis and Crohn's disease is decades old. Dr. LeLeiko is the site principal investigator of a multi-centered study aimed at enrolling and following 700 children under 16 years of age across 18 major medical centers to determine the effects of new treatments on the course of IBD.
He is also involved in basic laboratory research on the effect of nutrition on the expression of genes in the gastrointestinal tract.
Current research is primarily focused on studying the natural history of inflammatory bowel disease in the current therapeutic era. This is a multi-center study involving 18 pediatric gastrointestinal centers in the United States and Canada.
As principal investigator of this site's program, Dr. LeLeiko is responsible for the conduct of the study and meeting the quota of enrolling 60 newly diagnosed children under age 16 into the study.
The principle objective of the current program is to understand the factors influencing various disease-related outcomes.
The Natural History of Inflammatory Bowel Disease in Children: The Pediatric IBD Registry
Site P.I
Pediatric Inflammatory Bowel Disease Research Consortium(2002 Present)
Outcome of intravenous steroid therapy in ulcerative colitis individuals (OSCI)
Site P.I
Industry
2007-Present
"OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bowel Disease"
Co-Investigator - (Sands P.I.)
1R21DK078555-01 NIH NIDDK9/2007-9/2008
Ocean State Crohn's and Colitis Area Registry
Co-Investigator (Sands P.I.)
1 UO1 DP000340-03
CDC-CCFA 2007-2009
A Phase 3, Randomized, Open Label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Inflixamab (REMICADE) in Pediatric subjects with Moderately to Severely Active Ulcerative Colitis.
Clinical Protocol C0168T72
Site P.I. Centocor
2007 - Present
Retrospective Evaluation of the Safety and Efficacy of Adalimumab in the Treatment of Inflammatory Bowel Disesa in Children (RESEAT)
Site P.I.
Abbott
2007-Present
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatic Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HbeAg-positive.
Clinical Protocol AI463028
Site - Data Safety Monitor
Bristol Meyers Squibb
2007-present
